| Literature DB >> 19072222 |
Maria Katsara1, George Deraos, Theodore Tselios, Minos-Timotheos Matsoukas, Irene Friligou, John Matsoukas, Vasso Apostolopoulos.
Abstract
Altered peptide ligands that alter immune responses are a promising approach to the immunotherapy of multiple sclerosis. Cyclic peptides are of interest because the limited stability of linear peptides restricts their use in vivo. We designed and synthesized a cyclic double mutant peptide from MBP(87-99)-[cyclo(87-99)[A(91),A(96)]MBP(87-99)]. Immunization of mice, in CFA reduced Th1 responses. However, when conjugated to reduced mannan, a significant further reduction of Th1 responses and moderate Th2 responses were induced.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19072222 DOI: 10.1021/jm801250v
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446